blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3243821

EP3243821 - PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.01.2021
Database last updated on 31.03.2026
FormerThe patent has been granted
Status updated on  24.01.2020
FormerGrant of patent is intended
Status updated on  17.01.2020
FormerExamination is in progress
Status updated on  03.01.2020
FormerGrant of patent is intended
Status updated on  19.08.2019
FormerExamination is in progress
Status updated on  07.09.2018
FormerRequest for examination was made
Status updated on  13.10.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
GB006, Inc.
3013 Science Park Road, Suite 200
San Diego, CA 92121 / US
[2020/14]
Former [2019/36]For all designated states
GB006, Inc.
251 Little Falls Drive
Wilmington, New Castle 19808 / US
Former [2017/46]For all designated states
Adhaere Pharamaceuticals, Inc.
11950 S.W. 72nd Place
Pinecrest, FL 33156 / US
Inventor(s)01 / GUPTA, Vineet
Adhaere Pharmaceuticals, Inc
11950 S.W. 72nd Place
Pinecrest, FL 33156 / US
 [2017/46]
Representative(s)Murgitroyd & Company
165-169 Scotland Street
Glasgow G5 8PL / GB
[N/P]
Former [2020/09]Murgitroyd & Company
Murgitroyd House
165-169 Scotland Street
Glasgow G5 8PL / GB
Former [2017/46]chapman + co
18 Staple Gardens
Winchester, Hampshire SO23 8SR / GB
Application number, filing date17177006.802.05.2011
[2017/46]
Priority number, dateUS20100362363P08.07.2010         Original published format: US 362363 P
[2017/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3243821
Date:15.11.2017
Language:EN
[2017/46]
Type: B1 Patent specification 
No.:EP3243821
Date:26.02.2020
Language:EN
[2020/09]
Type: B8 Corrected title page of specification 
No.:EP3243821
Date:15.04.2020
[2020/16]
Search report(s)(Supplementary) European search report - dispatched on:EP11.08.2017
ClassificationIPC:C07D417/06, A61K31/427, A61P29/00
[2017/46]
CPC:
C07D417/06 (EP,US); A61K31/427 (CN); A61K31/5377 (CN);
A61P1/04 (EP); A61P11/06 (EP); A61P13/12 (EP);
A61P17/00 (EP); A61P17/02 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P19/04 (EP); A61P25/00 (EP);
A61P25/28 (EP); A61P29/00 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/10 (EP); A61P31/18 (EP);
A61P33/06 (EP); A61P35/00 (EP); A61P35/02 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P37/08 (EP);
A61P43/00 (EP); A61P7/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); A61P9/12 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/46]
TitleGerman:PHARMAZEUTISCHE FORMULIERUNGEN ZUR REGULIERUNG VON INTEGRIN-CD11B/CD18[2017/46]
English:PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18[2017/46]
French:FORMULATIONS PHARMACEUTIQUES POUR RÉGULER L'INTÉGRINE CD11B/CD18[2017/46]
Examination procedure20.06.2017Examination requested  [2017/46]
20.06.2017Date on which the examining division has become responsible
11.05.2018Amendment by applicant (claims and/or description)
07.09.2018Despatch of a communication from the examining division (Time limit: M04)
18.12.2018Reply to a communication from the examining division
26.03.2019Despatch of a communication from the examining division (Time limit: M04)
17.05.2019Reply to a communication from the examining division
20.08.2019Communication of intention to grant the patent
20.12.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.12.2019Fee for grant paid
20.12.2019Fee for publishing/printing paid
16.01.2020Information about intention to grant a patent
16.01.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP11803961.9  / EP2591092
Divisional application(s)EP20159424.9  / EP3682947
Opposition(s)27.11.2020No opposition filed within time limit [2021/05]
Fees paidRenewal fee
20.06.2017Renewal fee patent year 03
20.06.2017Renewal fee patent year 04
20.06.2017Renewal fee patent year 05
20.06.2017Renewal fee patent year 06
20.06.2017Renewal fee patent year 07
11.05.2018Renewal fee patent year 08
15.05.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.05.2011
AL26.02.2020
AT26.02.2020
CY26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
MK26.02.2020
MT26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
LU02.05.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
BE31.05.2020
IS26.06.2020
PT19.07.2020
[2022/31]
Former [2022/30]HU02.05.2011
AL26.02.2020
AT26.02.2020
CY26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
MT26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
LU02.05.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
BE31.05.2020
IS26.06.2020
PT19.07.2020
Former [2022/27]HU02.05.2011
AT26.02.2020
CY26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
MT26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
LU02.05.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
BE31.05.2020
IS26.06.2020
PT19.07.2020
Former [2021/24]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
LU02.05.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
BE31.05.2020
IS26.06.2020
PT19.07.2020
Former [2021/15]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
LU02.05.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2021/10]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/50]CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/49]CZ26.02.2020
DK26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/48]DK26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/47]DK26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
Former [2020/45]FI26.02.2020
HR26.02.2020
LV26.02.2020
NL26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
Former [2020/40]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
Former [2020/39]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
Former [2020/38]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
NO26.05.2020
GR27.05.2020
Former [2020/37]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
NO26.05.2020
Former [2020/35]FI26.02.2020
NO26.05.2020
Documents cited:Search[X] US2004002526  (KLEIN J PETER et al.)
 [A]   FARIDI MOHD H ET AL: "Identification of novel agonists of the integrin CD11b/CD18", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, vol. 19, no. 24, 15 December 2009 (2009-12-15), pages 6902 - 6906, XP026754144, ISSN: 0960-894X, [retrieved on 20091022], DOI: 10.1016/J.BMCL.2009.10.077

DOI:   http://dx.doi.org/10.1016/j.bmcl.2009.10.077
by applicant  "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
   "Remington's Pharmaceutical Sciences", 1990
   "The United States Pharmacopeia", 1999, THE NATIONAL FORMULARY
   MARCH: "Advanced Organic Chemistry", 1992, JOHN WILEY AND SONS
   CAREY; SUNDBERG: "Advanced Organic Chemistry", vol. A, B, 1990, PLENUM PRESS, INC
   GREEN; WUTS: "Protective groups in Organic Synthesis", 1991, JOHN WILEY AND SONS
   LAROCK: "Comprehensive Organic Transformations", 1988, VCH PUBLISHERS, INC.
   YANG, W.; C.V. CARMAN; M. KIM; A. SALAS; M. SHIMAOKA; T.A. SPRINGER: "A small molecule agonist of an integrin, alpha L beta 2.", J BIOL CHEM, 2006
   CANADAS, T.N.; X. CULLERE: "Neutrophil beta2 integrins: moderators of life or death decisions.", TRENDS IMMUNOL, vol. 26, no. 7, 2005, pages 388 - 95
   LEY, K. ET AL.: "Getting to the site of inflammation: the leukocyte adhesion cascade updated.", NAT REV IMMUNOL, vol. 7, no. 9, 2007, pages 678 - 89
   SIMON, D.I. ET AL.: "Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty", J CLIN INVEST, vol. 105, no. 3, 2000, pages 293 - 300
   CAO, C. ET AL.: "A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics.", BLOOD, vol. 106, no. 9, 2005, pages 3234 - 41
   TANG, T. ET AL.: "A role for Mac-1 (CDIIb/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis.", J EXP MED, vol. 186, no. 11, 1997, pages 1853 - 63
   PLOW, E.F ET AL.: "Ligand binding to integrins.", J BIOL CHEM, vol. 275, no. 29, 2000, pages 21785 - 8
   SORIANO, S.G. ET AL.: "Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury.", STROKE, vol. 30, no. 1, 1999, pages 134 - 9, XP055093139, DOI: doi:10.1161/01.STR.30.1.134

DOI:   http://dx.doi.org/10.1161/01.STR.30.1.134
   KUBOTA, Y ET AL.: "M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis.", J EXP MED, vol. 206, no. 5, 2009, pages 1089 - 102
   HYNES, R.O.: "Integrins: bidirectional, allosteric signaling machines", CELL, vol. 110, no. 6, 2002, pages 673 - 87
   ARNAOUT, M.A: "Leukocyte adhesion molecules deficiency: its structural basis, pathophysiology and implications for modulating the inflammatory response", IMMUNOL REV, vol. 114, 1990, pages 145 - 80
   PHILLIPSON, M ET AL.: "Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade", J EXP MED, vol. 203, no. 12, 2006, pages 2569 - 75
   AHN, G.O. ET AL.: "Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment.", PROC NATL ACAD SCI USA., vol. 107, no. 18, pages 8363 - 8
   OPHASCHAROENSUK, V. ET AL.: "Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation", KIDNEY INT, vol. 54, no. 2, 1998, pages 416 - 25
   LE HIR, M. ET AL.: "Podocyte bridges between the tuft and Bowman's capsule: an early event in experimental crescentic glomerulonephritis", J AM SOC NEPHROL, vol. 12, no. 10, 2001, pages 2060 - 71
   TANG, T. ET AL.: "A role for Mac-I (CDIIb/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor- dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis", J EXP MED, vol. 186, no. 11, 1997, pages 1853 - 63
   FAN, S.T.; T.S. EDGINGTON: "Coupling of the adhesive receptor CD11b/CD18 to functional enhancement of effector macrophage tissue factor response", J CLIN INVEST, vol. 87, no. 1, 1991, pages 50 - 7
   WHITLOCK, B.B. ET AL.: "Differential roles for alpha(M)beta(2) integrin clustering or activation in the control of apoptosis via regulation of akt and ERK survival mechanisms", J CELL BIOL, vol. 151, no. 6, 2000, pages 1305 - 20
   REZZONICO. R. ET AL.: "Ligation of CD11b and CD11c beta(2) integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-lbeta production in primary human monocytes through a pathway dependent on nuclear factor-kappaB", BLOOD, vol. 97, no. 10, 2001, pages 2932 - 40
   GUHA, M.; N. MACKMAN: "The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells", J BIOL CHEM, vol. 277, no. 35, 2002, pages 32124 - 32
   RUBEL, C ET AL.: "Fibrinogen-CD11b/GD18 interaction activates the NF-kappa B pathway and delays apoptosis in human neutrophils", EUR J IMMUNOL, vol. 33, no. 5, 2003, pages 1429 - 38
   KETTRITZ, R. ET AL.: "Integrins and cytokines activate nuclear transcription factor-kappaB in human neutrophils", J BIOL CHEM, vol. 279, no. 4, 2004, pages 2657 - 65
   GIANCOTTI, F.G.; E, RUOSLAHTI: "Integrin signaling", SCIENCE, vol. 285, no. 5430, 1999, pages 1028 - 32
   SHEIKH, S.; G.B, NASH: "Continuous activation and deactivation of integrin CD11b/CD18 during de novo expression enables rolling neutrophils to immobilize on platelets", BLOOD, vol. 87, no. 12, 1996, pages 5040 - 50
   JAESCHKE, H. ET AL.: "Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver", HEPATOLOGY, vol. 17, no. 5, 1993, pages 915 - 23
   ROGERS, C.; E.R. EDELMAN; D.I. SIMON: "A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits", PROC NATL ACAD SCI U S A, vol. 95, no. 17, 1998, pages 10134 - 9
   WILSON, I. ET AL.: "Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart", CIRCULATION, vol. 88, 1993, pages II372 - 9
   PLOW, E.F.; L. ZHANG: "A MAC-1 attack: integrin functions directly challenged in knockout mice", J CLIN INVEST, vol. 99, no. 6, 1997, pages 1145 - 6
   YONEKAWA, K.; J.M. HARLAN: "Targeting leukocyte integrins in human diseases", J LEUKOC BIOL, vol. 77, no. 2, 2005, pages 129 - 40
   DOVE, A.: "CD18 trials disappoint again", NAT BIOTECHNOL, vol. 18, no. 8, 2000, pages 817 - 8
   SHIMIZU, K. ET AL.: "Leukocyte integrin Mac-1 promotes acute cardiac allograft rejection", CIRCULATION, vol. 117, no. 15, 2008, pages 1997 - 2008
   RAMAMOORTHY, C. ET AL.: "CD18 adhesion blockade decreases bacterial clearance and neutrophil recruitment after intrapulmonary E. coli, but not after S. aureus", J LEUKOC BIOL, vol. 61, no. 2, 1997, pages 167 - 72
   LUM, A.F. ET AL.: "Dynamic regulation of LFA-1 activation and neutrophil arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow", J BIOL CHEM, vol. 277, no. 23, 2002, pages 20660 - 70
   ALLISON, M.: "PML problems loom for Rituxan", NAT BIOTECHNOL, vol. 28, no. 2, 2010, pages 105 - 6
   BANSAL, V.S. ET AL.: "Small molecule antagonists of complement receptor type 3 block adhesion and adhesion-dependent oxidative burst in human polymorphonuclear leukocytes", J PHARMACOL EXP THER, vol. 304, no. 3, 2003, pages 1016 - 24, XP055170322, DOI: doi:10.1124/jpet.102.045286

DOI:   http://dx.doi.org/10.1124/jpet.102.045286
   BJORKLUND, M. ET AL.: "Stabilization of the activated alphaMbeta2 integrin by a small molecule inhibits leukocyte migration and recruitment", BIOCHEMISTRY, vol. 45, no. 9, 2006, pages 2862 - 71, XP055046653, DOI: doi:10.1021/bi052238b

DOI:   http://dx.doi.org/10.1021/bi052238b
   FARIDI, M.H.: "Identification of novel agonists of the integrin CD11b/CD18", BIOORG MED CHEM LETT, 2009
   ARNAOUT, M.A. ET AL.: "Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol)", J CLIN INVEST, vol. 72, no. 1, 1983, pages 171 - 9
   WRIGHT, S.D. ET AL.: "Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies", PROC NATL ACAD SCI USA, vol. 80, no. 18, 1983, pages 5699 - 703, XP000654996, DOI: doi:10.1073/pnas.80.18.5699

DOI:   http://dx.doi.org/10.1073/pnas.80.18.5699
   HOGG, N. ET AL.: "A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-f", J CLIN INVEST, vol. 103, no. 1, 1999, pages 97 - 106
   DRANSFIELD, I.; N, HOGG: "Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits", EMBO J, vol. 8, no. 12, 1989, pages 3759 - 65
   COXON, A. ET AL.: "A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation", IMMUNITY, vol. 5, no. 6, 1996, pages 653 - 66
   PARK, J.Y.; M.A. ARNAOUT; V. GUPTA: "A simple, no-wash cell adhesion-based high-throughput assay for the discovery of small-molecule regulators of the integrin CD11b/CD18", J BIOMOL SCREEN, vol. 12, no. 3, 2007, pages 406 - 17
   GUPTA, V. ET AL.: "The beta-tail domain (betaTD) regulates physiologic ligand binding to integrin CD11b/CD18.", BLOOD, vol. 109, no. 8, 2007, pages 3513 - 20
   ALONSO, J.L. ET AL.: "Does the integrin alphaA domain act as a ligand for its betaA domain?", CURR BIOL, vol. 12, no. 10, 2002, pages R340 - 2
   GUPTA, V.: "HTS identification of compounds that enhance the binding of CD11b/CD18 to fibrinogen via a luminescence assay", PUBCHEM ASSAY ID, 2009, pages 1499
   CHEN, L.Y ET AL.: "Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter", HUM MOL GENET, vol. 12, no. 19, 2003, pages 2547 - 58
   BERGMEIER, W. ET AL.: "Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III", J CLIN INVEST, vol. 117, no. 6, 2007, pages 1699 - 707
   SZCZUR, K. ET AL.: "Rho GTPase CDC42 regulates directionality and random movement via distinct MAPK pathways in neutrophils", BLOOD, vol. 108, no. 13, 2006, pages 4205 - 13
   ZIGMOND, S.H.: "Orientation chamber in chemotaxis", METHODS ENZYMOL, vol. 162, 1988, pages 65 - 72
   PLUSKOTA, E. ET AL.: "Neutrophil apoptosis: selective regulation by different ligands of integrin alphaMbeta2", J IMMUNOL, vol. 181, no. 5, 2008, pages 3609 - 19
   LI, R.; M.A. ARNAOUT: "Functional analysis of the beta 2 integrins", METHODS MOL BIOL, vol. 129, 1999, pages 105 - 24
   XIONG, J.P. ET AL.: "An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain", J BIOL CHEM, vol. 275, no. 49, 2000, pages 38762 - 7, XP002905767, DOI: doi:10.1074/jbc.C000563200

DOI:   http://dx.doi.org/10.1074/jbc.C000563200
   LU, C. ET AL.: "Epitope mapping of antibodies to the C-terminal region of the integrin beta 2 subunit reveals regions that become exposed upon receptor activation.", J IMMUNOL, vol. 166, no. 9, 2001, pages 5629 - 37
   XIONG, J.P. ET AL.: "New insights into the structural basis of integrin activation", BLOOD, vol. 102, no. 4, 2003, pages 1155 - 9, XP055224905, DOI: doi:10.1182/blood-2003-01-0334

DOI:   http://dx.doi.org/10.1182/blood-2003-01-0334
   SEMMRICH, M. ET AL.: "Importance of integrin LFA-1 deactivation for the generation of immune responses", J EXP MED, vol. 201, no. 12, 2005, pages 1987 - 98
   GABELER, E.E. ET AL.: "A comparison of balloon injury models of endovascular lesions in rat arteries", BMC CARDIOVASC DISORD, vol. 2, 2002, pages 16, XP021015219, DOI: doi:10.1186/1471-2261-2-16

DOI:   http://dx.doi.org/10.1186/1471-2261-2-16
   RENSHAW, S.A. ET AL.: "A transgenic zebrafish model of neutrophilic inflammation", BLOOD, vol. 108, no. 13, 2006, pages 3976 - 8, XP002447426, DOI: doi:10.1182/blood-2006-05-024075

DOI:   http://dx.doi.org/10.1182/blood-2006-05-024075
   NUSSLEIN-VOLHARD, C.: "Practical Approach Series", 2002, OXFORD UNIVERSITY PRESS, article "Zebrafish - A Practical Approach"
   LEE, J.O. ET AL.: "Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18).", CELL, vol. 80, no. 4, 1995, pages 631 - 8, XP002920554, DOI: doi:10.1016/0092-8674(95)90517-0

DOI:   http://dx.doi.org/10.1016/0092-8674(95)90517-0
   WEITZ-SCHMIDT, G. ET AL.: "Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site", NAT MED, vol. 7, no. 6, 2001, pages 687 - 92
   LEE, J.O. ET AL.: "Two conformations of the integrin A-domain (1-domain): a pathway for activation?", STRUCTURE, vol. 3, no. 12, 1995, pages 1333 - 40, XP004587940, DOI: doi:10.1016/S0969-2126(01)00271-4

DOI:   http://dx.doi.org/10.1016/S0969-2126(01)00271-4
   SHIMAOKA, M. ET AL.: "Stabilizing the integrin alpha M inserted domain in alternative conformations with a range of engineered disulfide bonds", PROC NATL ACAD SCI U S A, vol. 99, no. 26, 2002, pages 16737 - 41
   MCCLEVERTY, C.J.; R.C. LIDDINGTON: "Engineered allosteric mutants of the integrin alphaMbeta2 I domain: structural and functional studies", BIOCHEM J, vol. 372, 2003, pages 121 - 7
   SHERMAN, W. ET AL.: "Novel procedure for modeling ligand/receptor induced fit effects", J MED CHEM, vol. 49, no. 2, 2006, pages 534 - 53, XP055186996, DOI: doi:10.1021/jm050540c

DOI:   http://dx.doi.org/10.1021/jm050540c
   KEVIN, J.B. ET AL.: "Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters", PROCEEDINGS OF THE ACM/IEEE CONFERENCE ON SUPERCOMPUTING (SC06), TAMPA, FLORIDA, 11 November 2006 (2006-11-11)
   BARNARD, J.W. ET AL.: "Neutrophil inhibitory factor prevents neutrophil-dependent lung injury", J IMMUNOL, vol. 155, no. 10, 1995, pages 4876 - 81
   ZERRIA, K. ET AL.: "Recombinant integrin CD11b A-domain blocks polymorphonuclear cells recruitment and protects against skeletal muscle inflammatory injury in the rat", IMMUNOLOGY, vol. 119, no. 4, 2006, pages 431 - 40
   FENG, Y. ET AL.: "Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1", J BIOL CHEM, vol. 273, no. 10, 1998, pages 5625 - 30
   LI, R. ET AL.: "Two functional states of the CD11b A-domain: correlations with key features of two Mn2+-complexed crystal structures.", J CELL BIOL, vol. 143, no. 6, 1998, pages 1523 - 34, XP002209418, DOI: doi:10.1083/jcb.143.6.1523

DOI:   http://dx.doi.org/10.1083/jcb.143.6.1523
   ABAD-ZAPAFERO, C.; J.T. METZ: "Ligand efficiency indices as guideposts for drug discovery", DRUG DISCOV TODAY, vol. 10, no. 7, 2005, pages 464 - 9, XP004871769, DOI: doi:10.1016/S1359-6446(05)03386-6

DOI:   http://dx.doi.org/10.1016/S1359-6446(05)03386-6
   FRIESNER, R.A. ET AL.: "Glide: a new approach for rapid. accurate docking and scoring. 1. Method and assessment of docking accuracy.", J MED CHEM, vol. 47, no. 7, 2004, pages 1739 - 49, XP002592019, DOI: doi:10.1021/JM0306430

DOI:   http://dx.doi.org/10.1021/JM0306430
   GUIMARAES, C.R.; M. CARDOZO: "MM-GB/SA rescoring of docking poses in structure-based lead optimization", J CHEM INF MODEL, vol. 48, no. 5, 2008, pages 958 - 70
   LIU, L. ET AL.: "Requirement for RhoA kinase activation in leukocyte de-adhesion", J IMMUNOL, vol. 169, no. 5, 2002, pages 2330 - 6
   HUTTENLOCHER, A.; M.H. GINSBERG; A.F. HORWITZ: "Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity.", J CELL BIOL, vol. 134, no. 6, 1996, pages 1551 - 62
   PALECEK, S.P. ET AL.: "Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness", NATURE, vol. 385, no. 6616, 1997, pages 537 - 40
   PARK. E.J. ET AL.: "Aberrant activation of integrin alpha4beta7 suppresses lymphocyte migration to the gut", J CLIN INVEST, vol. 117, no. 9, 2007, pages 2526 - 38
   DE BRUYN, K.M. ET AL.: "The small GTPase Rapt is required for Mn(2+)-and antibody-induced LFA-1- and VLA-4-mediated cell adhesion", J BIOL CHEM, vol. 277, no. 33, 2002, pages 29468 - 76
   LEFORT, C.T. ET AL.: "Outside-in signal transmission by conformational changes in integrin Mac-1", J IMMUNOL, vol. 183, no. 10, 2009, pages 6460 - 8
   WANG, Y. ET AL.: "Leukocyte engagement of platelet glycoprotein lbalpha via the integrin Mac-1 is critical for the biological response to vascular injury", CIRCULATION, vol. 112, no. 19, 2005, pages 2993 - 3000
   KUIJPERS, T.W. ET AL.: "Freezing adhesion molecules in a state of high-avidity binding blocks eosinophil migration", J EXP MED, vol. 178, no. 1, 1993, pages 279 - 84
   PARK, E.J. ET AL.: "Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes.", BLOOD, vol. 115, no. 8, 2010, pages 1572 - 81
   HAN C. JIN J; XU S; LIU H; LI N; CAO X.: "Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b", NAT IMMUNOL., vol. 11, no. 8, pages 734 - 42
   CAO C; GAO Y; LI Y; ANTALIS TM; CASTELLINO FJ; ZHANG L.: "The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD1 1 b.", J CLIN INVEST., vol. 120, no. 6, pages 1971 - 80
   MEANS TK; LUSTER AD.: "Integrins limit the Toll", NAT IMMUNOL, vol. 11, no. 8, pages 691 - 3
   DRIESSENS MH; VAN HULTEN P; ZUURBIER A; LA RIVIERE G; ROOS E.: "Inhibition and stimulation of LFA-1 and Mac-1 functions by antibodies against murine CD18. Evidence that the LFA-1 binding sites for ICAM-1, -2, and - 3 are distinct.", J LEUKOC BIOL, vol. 60, no. 6, 1996, pages 758 - 65
   REICHERT F; SLOBODOV U; MAKRANZ C; ROTSHENKER S.: "Modulation (inhibition and augmentation) of complement receptor-3-mediated myelin phagocytosis.", NEUROBIOL DIS., vol. 8, no. 3, 2001, pages 504 - 12
   PAVLOVIC MD; COLIC M; PEJNOVIC N; TAMATANI T; MIYASAKA M; DUJIC A.: "A novel anti-rat CD18 monoclonal antibody triggers lymphocyte homotypic aggregation and granulocyte adhesion to plastic: different intracellular signaling pathways in resting versus activated thymocytes.", EUR J IMMUNOL., vol. 24, no. 7, 1994, pages 1640 - 8
   STOCK! J; MAJDIC O; PICKL WF; ROSENKRANZ A; PRAGER E; GSCHWANTLER E ET AL.: "Granulocyte activation via a binding site near the C-terminal region of complement receptor type 3 alpha-chain (CD11b) potentially involved in intramembrane complex formation with glycosylphosphatidylinositol-anchored Fc gamma RIIIB (CD16) molecules", J IMMUNOL., vol. 154, no. 10, 1995, pages 5452 - 63
   PETRUZZELLI L; MADUZIA L; SPRINGER TA: "Activation of lymphocyte function-associated molecule-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) mimicked by an antibody directed against CD18", J IMMUNOL, vol. 155, no. 2, 1995, pages 854 - 66, XP002209615
   KEIZER GD; VISSER W; VLIEM M; FIGDOR CG.: "A monoclonal antibody (NKI-L16) directed against a unique epitope on the alpha-chain of human leukocyte function-associated antigen 1 induces homotypic cell-cell interactions", J IMMUNOL., vol. 140, no. 5, 1988, pages 1393 - 400
   ANDREW D; SHOCK A; BALL E; ORTLEPP S; BELL J; ROBINSON M.: "KIM185, a monoclonal antibody to CD18 which induces a change in the conformation of CD18 and promotes both LFA-1- and CR3-dependent adhesion", EUR J IMMUNOL., vol. 23, no. 9, 1993, pages 2217 - 22
   ROBINSON MK; ANDREW D; ROSEN H; BROWN D; ORTLEPP S; STEPHENS P ET AL.: "Antibody against the Leu-CAM beta-chain (CD18) promotes both LFA-- 1- and CR3-dependent adhesion events", J IMMUNOL., vol. 148, no. 4, 1992, pages 1080 - 5
   DRANSFIELD I; HOGG N.: "Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits", EMBO J., vol. 8, no. 12, 1989, pages 3759 - 65
   BAZIL V; STEFANOVA I; HILGERT I; KRISTOFOVA H; VANEK S; HOREJSI V.: "Monoclonal antibodies against human leucocyte antigens, IV. Antibodies against subunits of the LFA-1 (CD11a/CD18) leucocyte-adhesion glycoprotein.", FOLIA BIOL (PRAHA, vol. 36, no. 1, 1990, pages 41 - 50
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.